ClinicalTrials.gg
Status unknownNCT05144178EHS-StrategyUpdated Jan 3, 2022

Insight Into the UAE Experience With Monoclonal Antibodies (Sotrovimab )

An observational study in COVID-19 Respiratory Infection, sponsored by Emirates Health Services (EHS). Status unknown at 1 site in United Arab Emirates. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2022-01-03.

Sponsored by Emirates Health Services (EHS) · Observational

How we know

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,500
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in COVID-19 with a site in United Arab Emirates — none open to participants now, 1 under way, 1 of them phase 3. COVID-19 · United Arab Emirates.

Started
2021
with 11 others
Observational
7 of 26
none open now
Registered
14th of 26
by date
Lead sponsor
1 of 26
Emirates Health Services (EHS)

Among the 26 studies in COVID-19 with a site in United Arab Emirates, this one is one of 12 that started in 2021, is one of 7 observational ones, and was the 14th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 26 studies in COVID-19 with a site in United Arab Emirates is open now. The open studies under COVID-19, anywhere →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies in COVID-19 with a site in United Arab Emirates as a file.
02

Study summary

Sotrovimab is a newly developed monoclonal antibody for the treatment of mild and moderate COVID-19 patient, who are at high risk for progression to severe COVID-19, including hospitalization or death. This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions.

The safety and effectiveness of this investigational therapy continues to be evaluated for treatment of COVID-19. Sotrovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19.

As the clinical trial results are too preliminary for the drug to enter routine use in UAE the drug approved only for emergency use, until further evidence shows Sotrovimab is effective, so we thought about this study as a tool to assess the success of Emirats Health service (EHS) strategy for fighting against COVID-19 outside the hospital setting.

Read the detailed description

May 26, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19), as described in the Scope of Authorization (Section II) of this letter, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3).

May 28,2021 the UAE Ministry of Health and Prevention approved the investigational drug for emergency use, and Emirats health service considered strategy for fighting against COVID-19 outside the hospital setting, based on this strategy ,special protocol was finalized and approved including initiation of infusion units for the drug in EHS hospital and primary health care centers, all Infection Prevention and Control Precautions were taken inconsideration .

The overall aim of this study is to determine the effectiveness of Sotrovimab infusion in cohort of ambulatory patients with early symptomatic COVID-19 at high risk for hospitalization, in UAE. We expect to assess the Proportion of patients who have progression of COVID-19 through 28 days as defined by visit to a hospital emergency room for management or illness, or hospitalization more than 24 h for acute management of illness or death. files of patients treated from June 2021 till October 2021 will be reviewed and data will be collected based on the protocol approved from MOHAP ethical committee.

03

Conditions studied

  • COVID-19 Respiratory Infection

Browse trials for

Keywords

  • Sotrovimab
  • UAE experience
  • Emirates health service EHS strategy
  • Out patient treatment for COVID
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The source population will consist of individuals residing in UAE ,infected with SARS-CoV-2 and developed mild or moderate symptoms and are high risk .

High risk patients are defined as meeting at least 1 of the following criteria:

  1. BMI ≥ 25
  2. Chronic kidney disease
  3. Diabetes
  4. Immunosuppressive disease
  5. Receiving immunosuppressive treatment
  6. Age ≥ 65 years
  7. Age ≥ 55 years and have cardiovascular disease, hypertension, or COPD/chronic respiratory disease.
  8. pregnancy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All cases received Sotrovimab according the EUA protocol.
  • All patient aged 13 and above

Exclusion criteria

Exclusion Criteria:

  • Sever form of the COVID-19 disease
  • Hospitalized patient
  • Age less than 13 years old
  • less than 25 and no risk factors
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Mild and moderated COVID -19 patient treated out side the hospital sitting

    Reviewing files of such group that had been received Sotrovimab

06

What researchers measure

Primary outcomes

  1. percent of hospital admission from total number of reviewed patient

    Admission to hospital with progressive COVID -19 more than 24h

    Time frame: 10 days

  2. percent of Death among total number of reviewed patient

    mortality post treatment

    Time frame: 28 days

07

Study locations

1 of 1 sites recruiting
  • Emirats Health Service
    Dubai, United Arab Emirates
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Jan 2022, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2021
First posted
Dec 3, 2021
StartActual
Nov 14, 2021
Primary completionEst.
Jan 30, 2022
CompletionEst.
Feb 9, 2022
Last update
Jan 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05144178
Lead sponsor
Emirates Health Services (EHS)
Responsible party
Dr. Sumaya Abdalateef (Clinical Director, Emirates Health Services (EHS)) — Principal investigator
First posted
Dec 3, 2021
Start date
Nov 14, 2021
Primary completion
Jan 30, 2022 (estimated)
Completion
Feb 9, 2022 (estimated)
Last update
Jan 3, 2022

Study contacts

ghada Ali
Contact
ghada.ali@ehs.gov.ae
00971505194990
sumaya abdalateef
principal investigator · Emirats Health Service (EHS)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion